| scholarly article | Q13442814 |
| P356 | DOI | 10.1179/2295333715Y.0000000009 |
| P698 | PubMed publication ID | 26166681 |
| P2093 | author name string | J De Roover | |
| C Van Laer | |||
| N Boeckx | |||
| S Pauwels | |||
| B Wilmsen | |||
| K Bruyninckx | |||
| P2860 | cites work | Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. | Q31012437 |
| Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). | Q34310190 | ||
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. | Q37026032 | ||
| Harmonization of molecular monitoring of CML therapy in Europe | Q37587749 | ||
| Standardized definitions of molecular response in chronic myeloid leukemia. | Q38002704 | ||
| Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia | Q38186336 | ||
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial | Q42613611 | ||
| Evaluation of the Cepheid GeneXpert BCR-ABL assay | Q42793913 | ||
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial | Q42851077 | ||
| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia | Q44611047 | ||
| Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia | Q46090252 | ||
| Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. | Q53042357 | ||
| Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. | Q54313466 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 237-243 | |
| P577 | publication date | 2015-07-13 | |
| P1433 | published in | Acta Clinica Belgica | Q15757609 |
| P1476 | title | Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy | |
| P478 | volume | 70 |
| Q38762631 | Present and future of molecular monitoring in chronic myeloid leukaemia | cites work | P2860 |
Search more.